Health: pharmaceuticals; choice of formulation, dosage, and route of administration for opioid antagonists by certain persons and governmental entities if department of health and human services distributes opioid antagonists free of charge; allow. Creates new act.
House Bill 4428 would require the Michigan Department of Health and Human Services, when it distributes opioid antagonists at no cost to a person or governmental entity for overdose prevention, to let the recipient choose the formulation, delivery device, method of administration, or dosage of the medication they receive. The bill defines “opioid antagonist” as an FDA-approved drug used for the emergency treatment of a known or suspected opioid overdose, and it defines “opioid-related overdose” broadly to include severe symptoms such as respiratory depression, coma, or death.
The measure is aimed at improving access to overdose-reversal medications and ensuring that local agencies, organizations, or other recipients receive the version of the medication that best fits their needs. It also includes a safeguard stating that the choice requirement does not apply if allowing such choice would jeopardize the department’s receipt of federal funding. In effect, the bill creates a new statutory requirement governing how the department distributes free opioid antagonists, while preserving compliance with federal grant conditions.
If enacted, the bill would add a new act directing the Department of Health and Human Services’ distribution practices for free opioid antagonists. It would not broadly change criminal law or controlled-substance rules, but it would affect state public health administration by requiring recipient choice over naloxone-type products, subject to federal funding limits. The practical impact would fall on DHHS, local governments, and other entities receiving overdose-reversal medication through state programs, potentially influencing procurement, inventory, and distribution policies.
The available context suggests the bill is generally supportive of overdose prevention and access to life-saving medication. The bill’s structure reflects a policy preference for flexibility and recipient choice, which is typically viewed favorably by public health advocates and local entities that distribute naloxone. No committee transcript or vote record is provided, so there is no direct evidence of opposition or amendment debate in the materials supplied.
The main point of potential contention is the balance between recipient choice and administrative or funding constraints. The bill requires DHHS to allow choice in formulation, delivery device, administration method, or dosage, but only so far as that does not threaten federal funding. That carveout suggests concern about federal program requirements, procurement uniformity, or cost and supply management. Any opposition would likely focus on implementation complexity, product standardization, or the risk that expanded choice could complicate compliance with federal grant conditions.